Screening of Cardiac Arrhythmias With Wrist-worn Aino ECG Cardiac Monitor
6. června 2022 aktualizováno: PulseOn Oy
The study investigates the performance pf PulseOn Arrhythmia Monitor System that includes a wrist-worn device, which combines continuous optical heartbeat interval monitoring and intermittent ECG measurement, and a data management system used by healthcare professionals for data observation, in the detection of previously undiagnosed cardiac arrhythmias, especially atrial fibrillation.
Přehled studie
Postavení
Nábor
Podmínky
Intervence / Léčba
Detailní popis
The study consists of monitoring voluntary subjects with PulseOn Arrhythmia Monitoring System for the period of two weeks. The subjects are recruited mainly through newspaper advertisements. The study is executed in Tampere and Helsinki areas, Finland.
During the two week monitoring time, the subjects are instructed to wear the wrist device continuously, except when taking the device off e.g. for going to sauna or swimming, and for charging. The subjects are instructed to perform a 35-second ECG measurement (recording) in three cases:
- Scheduled recording four times a day
- In case of suspecting arrhythmic event, i.e. feeling symptoms
- In case the wrist device instructs to perform a recording by vibrating and showing an LED light
The data collected in the study is analysed post-hoc. In the post-hoc analysis, the cardiac rhythm assessed automatically from the ECG measurements is visually confirmed by a cardiologist.
Typ studie
Intervenční
Zápis (Očekávaný)
200
Fáze
- Nelze použít
Kontakty a umístění
Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.
Studijní kontakt
- Jméno: Antti Vehkaoja, DSc (tech)
- Telefonní číslo: +358407393181
- E-mail: antti.vehkaoja@pulseon.fi
Studijní místa
-
-
-
Tampere, Finsko
- Nábor
- Tampere Heart Hospital
-
Kontakt:
- Research coordinator at Heart Hospital
- Telefonní číslo: +358417306125
-
-
Kritéria účasti
Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.
Kritéria způsobilosti
Věk způsobilý ke studiu
50 let až 99 let (Dospělý, Starší dospělý)
Přijímá zdravé dobrovolníky
Ano
Pohlaví způsobilá ke studiu
Všechno
Popis
Inclusion Criteria for the main study group:
- At least 65 years of age
- Self-assessed ability to use the study devices
- Ability to give informed consent
- Volunteering for the study
Inclusion criteria for the active endurance athlete group:
- Minimum of 10 years of active training of endurance sport (e.g. long distance running, skiing, cycling, triathlon…) and currently an average amount of training of at least 10 hours a week.
- Age: ≥ 50 years
- Self-assessed ability to use the study devices
- Ability to give informed consent
- Volunteering for the study
Exclusion Criteria for both groups:
- Cardiac pacemaker
- Earlier diagnosis of atrial fibrillation
- Inability to give informed consent
- Denial
Studijní plán
Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.
Jak je studie koncipována?
Detaily designu
- Primární účel: Promítání
- Přidělení: Nerandomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Main study group
Normal subjects of at least 65 years of age
|
Wearing of the wrist device for a period of two weeks
|
|
Experimentální: Endurance athlete group
Group consists of active endurance athletes of at least 50 years of age
|
Wearing of the wrist device for a period of two weeks
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Diagnostic performance improvement with continuous optical measurement
Časové okno: Duration of patient measurement, i.e. two weeks
|
Percentual improvement in the performance of detecting previously undiagnosed atrial fibrillation in the study population by the continuous PPG-based heartbeat interval monitoring when compared with relying only on scheduled and symptom -based ECG measurements.
Cardiac rhythm assessed by a cardiologist from the ECG measurements that are made as a result of PPG-based arrhythmia notifications is compared with rhythm assessments made only from the scheduled and symptom-based ECG measurements.
It is evaluated whether more subjects can be diagnosed having atrial fibrillation with the help of continuous PPG-based rhythm monitoring.
|
Duration of patient measurement, i.e. two weeks
|
|
Validation of the clinical performance of PulseOn Arrhythmia Monitor System in general population by showing the adequacy of the obtained ECG data for clinical decision making.
Časové okno: Duration of patient measurement, i.e. two weeks
|
Data recorded by the study subjects during the two-week study time is assessed by a cardiologist and subjects are classified as having: "no observed arrhythmias", "atrial fibrillation episode(s)", "other potential arrhythmia", or "unconfident assessment" (due to the quality or lack of data).
The percentage of "unconfident assessment" shall be less than 20% of the subjects.
|
Duration of patient measurement, i.e. two weeks
|
|
Validation of the clinical performance of PulseOn Arrhythmia Monitor System in general population by showing sufficient patient convenience for using the device for the intended duration of two weeks
Časové okno: Duration of patient measurement, i.e. two weeks
|
The feedback from the subjects should show at least grade 3 in a scale of 1-5 for the "comfortability of using the wrist device".
|
Duration of patient measurement, i.e. two weeks
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Showing the benefit of the combined wrist-worn PPG and ECG solution in detecting other cardiac arrhythmias than atrial fibrillation.
Časové okno: Duration of patient measurement, i.e. two weeks
|
The visual ECG-based rhythm annotation made by a cardiologist is compared with simultaneous PPG-algorithm alarm state.
The incidence of notifications for other arrhythmias than atrial fibrilation is reported.
|
Duration of patient measurement, i.e. two weeks
|
|
Evaluation of the necessity of performing scheduled ECG measurements in addition to ECG measurements triggered by PPG-based arrhythmia notifications for detecting atrial fibrillation.
Časové okno: Duration of patient measurement, i.e. two weeks
|
Evaluation is done by comparing the atrial fibrillation detection outcome when considering only the PPG-triggered and symptom-based ECG measurements or when considering also the scheduled ECG measurements.
The outcome parameter is the number of subjects that would have been left undetected if the scheduled ECG measurements were not taken.
|
Duration of patient measurement, i.e. two weeks
|
|
Feedback about the usability of the evaluated solution from study subjects.
Časové okno: At the end of the 2-week measurement period
|
Feedback questions in scale of 1-5 and open-ended feedback.
Easiness of use of the wrist device, understandability of the user interface, suitability of the user materials, and unobtrusiveness.
|
At the end of the 2-week measurement period
|
|
Feedback about the usability of the evaluated solution from study personnel.
Časové okno: At the end of the study i.e. the end of 2022.
|
Feedback questions in scale of 1-5 and open-ended feedback.
Easiness of use of the data management service, suitability of the user materials.
|
At the end of the study i.e. the end of 2022.
|
|
Quality of the measured ECG signals
Časové okno: Duration of patient measurement, i.e. two weeks
|
Percentage of the ECG measurements classified as inadequate quality for rhythm assessment either an ECG analysis algorithm or by a doctor.
|
Duration of patient measurement, i.e. two weeks
|
|
Assessment of the subjects' adherence in using the solution.
Časové okno: Duration of patient measurement, i.e. two weeks
|
Analysis of how well the participants will follow the study protocol and do the participants register their ECG in correlation with the wrist device notification.
The outcome parameter is the percentage of scheduled and PPG-based notifications to take an ECG measurement and the variation of the percentage between the subjects.
|
Duration of patient measurement, i.e. two weeks
|
|
Benefit of optical measurement for the speed of detecting atrial fibrillation
Časové okno: Duration of patient measurement, i.e. two weeks
|
Comparison of the time to the first detection of atrial fibrillation or other arrhythmia when considering PPG-triggered ECG measurements or when considering the scheduled ECG measurements.
|
Duration of patient measurement, i.e. two weeks
|
|
Evaluation of the accuracy of automatic ECG analysis algorithms when comparing with manual annotations by a cardiologist.
Časové okno: Duration of patient measurement, i.e. two weeks
|
The automated assessment done for the 30-second ECG recordings is compared with the visual assessment to calculate the sensitivity and specificity for each rhythm category.
|
Duration of patient measurement, i.e. two weeks
|
Spolupracovníci a vyšetřovatelé
Zde najdete lidi a organizace zapojené do této studie.
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Vesa Virtanen, PhD (med), Heart Hospital of Tampere University Hospital
Termíny studijních záznamů
Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.
Hlavní termíny studia
Začátek studia (Aktuální)
22. května 2022
Primární dokončení (Očekávaný)
31. prosince 2022
Dokončení studie (Očekávaný)
31. prosince 2022
Termíny zápisu do studia
První předloženo
18. listopadu 2021
První předloženo, které splnilo kritéria kontroly kvality
18. ledna 2022
První zveřejněno (Aktuální)
19. ledna 2022
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
7. června 2022
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
6. června 2022
Naposledy ověřeno
1. června 2022
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- AinoScreening
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
NE
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Ne
Studuje produkt zařízení regulovaný americkým úřadem FDA
Ne
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .